Target Discovery Working With MD Anderson, EVMS to Develop Isoform-Based Cancer Dxs | GenomeWeb

Two years after completing proof-of-concept experiments for its IDBEST technology, Target Discovery has formed collaborations with the MD Anderson Cancer Center and the Eastern Virginia Medical School to develop protein isoform-based diagnostics for breast, prostate and ovarian cancer.

The Palo Alto, Calif.-based company is currently picking a list of biomarkers that will be examined for isoform differences. Researchers will then whittle down the markers to two or three promising isoforms on which to perform a larger validation study.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.